Results 181 to 190 of about 4,908 (210)

ChemInform Abstract: Asymmetric Synthesis of the Novel Antidepressant Rolipram

ChemInform, 1994
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
openaire   +3 more sources

Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram

Pharmacology Biochemistry and Behavior, 1995
The discriminative stimulus properties of the specific type IV phosphodiesterase inhibitor, rolipram, and its two stereoisomers were assessed using standard two-lever drug discrimination procedures in which responding on the appropriate lever was reinforced on a FR10 schedule.
David N. Stephens, Herbert Schneider, John S. Andrews, Motonori Yamaguchi   +3 more
openaire   +3 more sources

Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression

Nordic Journal of Psychiatry, 1992
To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate
B. Mejer-Nielsen, P. Arup, A. Korner, M. Schratzer, K. Behnke, M. Sastre-Y-Hernández, B. Voet, R. Bischoff, A. Geisler   +8 more
openaire   +2 more sources

Results of a Phase II Study of the Antidepressant Effect of Rolipram

Pharmacopsychiatry, 1984
The antidepressant effect of rolipram, believed to be based on a new mechanism of action, was investigated in an open phase II study in 10 depressive patients, most of whom had been refractory to previous antidepressant therapy. Five patients displayed a good to very good improvement of their depressive condition.
B Pflug, H J Stief, E Zeller, M Sastre-y-Hernández   +3 more
openaire   +2 more sources

Mapping of second messenger and rolipram receptors in mammalian brain

Brain Research Bulletin, 1992
Autoradiographic localizations of major second messengers and a selective cyclic adenosine monophosphate (cyclic-AMP) phosphodiesterase in the brain were visualized in the gerbil and the rat using receptor autoradiography. [3H]Phorbol 12,13-dibutyrate (PDBu), [3H]inositol 1,4,5-trisphosphate (IP3), [3H]forskolin, [3H]cyclic-AMP, and [3H]rolipram were ...
Hiroyuki Kato, Tsutomu Araki, Kyuya Kogure   +2 more
openaire   +3 more sources

Enhancement of the relative uptake of18F-FDG in mouse fibrosarcoma by rolipram

Annals of Nuclear Medicine, 2002
The effect of rolipram, a selective phosphodiesterase type 4 inhibitor, on the uptake of 18F-fluorodeoxyglucose (18F-FDG) in tumor tissue was examined in mice transplanted with NFSa fibrosarcoma. The uptake indexes of 18F-FDG in the heart, skeletal muscle and brain remarkably decreased after treatment with 3 mg/kg of rolipram (heart: 13%, skeletal ...
Rie Hosoi, Tsunehiko Nishimura, Sachiko Koike, Koichi Ando, Osamu Inoue, Kaoru Kobayashi, Sotaro Momosaki   +6 more
openaire   +3 more sources

Involvement of Rolipram-Sensitive Cyclic AMP Phosphodiesterase in the Regulation of Cardiac Contraction

Journal of Cardiovascular Pharmacology, 1990
The involvement of rolipram-sensitive phosphodiesterase (PDE IV) in regulation of cardiac contraction was investigated by studying the effect of selective inhibitors (rolipram, denbufylline, Ro 20-1724) on guinea pig left atria contraction. In contrast to milrinone and SK&F 94120 (inhibitors of the cyclic GMP-inhibited PDE, PDE III), (+/-)-rolipram and
Bernard Muller, Claire Lugnier, Jean-Claude Stoclet   +2 more
openaire   +3 more sources

Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in parkinson's disease

Pharmacological Research Communications, 1983
The effects of Rolipram, a new phosphodiesterase inhibitor, were assessed in a double-blind trial versus placebo in 10 patients with Parkinson's disease already under treatment. Contrary to previous findings with specific phosphodiesterase inhibitors, with Rolipram (at the dose of 3 mg per day), no significant deterioration of the therapeutic action of
G. Meco, Alessandro Agnoli, Massimo Casacchia, L. Bedini, Castellana F, G. Cusimano   +5 more
openaire   +3 more sources

Comparision of the Inotropic Effects of Levosimendan, Rolipram, and Dobutamine on Human Atrial Trabeculae

Journal of Cardiovascular Pharmacology, 2004
The aim of this study was to compare the positive inotropic effects of 3 different agents with 3 different mechanisms of actions-levosimendan, rolipram, and dobutamine-on human atrial trabecular muscles. Samples of right atrial appendage (1 cm, 500-1000 mg) were removed and immersed in preoxygenated and modified Tyrode solution.
Coskun Usta, PUDDU, Paolo Emilio, PAPALIA, Ugo, Vincenzo De Santis, Domenico Vitale, TRITAPEPE, Luigi, MAZZESI, Giuseppe, MIRALDI, Fabio, Sadi S. Ozdem   +8 more
openaire   +3 more sources

Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram.

The Journal of Pharmacology and Experimental Therapeutics, 1996
It is now generally accepted that the renin secretory response to beta adrenoceptor stimulation is mediated by increased formation of cAMP in the juxtaglomerular cells. It is also known that renin secretion is increased when cAMP metabolism is decreased by phosphodiesterase inhibitors such as theophylline, but it is not known which isoforms of ...
N, Chiu, I, Park, I A, Reid
openaire   +2 more sources